EPHB2 and neoplasm: An array of EphB2 mutants were used to evaluate the role of receptor forward and reverse signaling on tumor formation (Figure 2a): 1) EphB2(K662R)—kinase domain inactivated and inhibited in forward signaling but retaining ephrin-mediated reverse signaling19.